Seer, Inc. (NASDAQ:SEER) major shareholder Growth Fund Limited Part Amoon sold 835,278 shares of the business’s stock in a transaction that occurred on Wednesday, June 9th. The shares were sold at an average price of $30.00, for a total value of $25,058,340.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Major shareholders that own 10% or more of a company’s stock are required to disclose their transactions with the SEC.
Shares of Seer stock opened at $33.77 on Friday. Seer, Inc. has a 12-month low of $26.48 and a 12-month high of $86.55. The business’s 50 day moving average is $41.02. The company has a market cap of $2.07 billion and a PE ratio of -13.62.
Seer (NASDAQ:SEER) last posted its quarterly earnings results on Monday, May 10th. The company reported ($0.27) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.08). The company had revenue of $0.06 million during the quarter. During the same period in the previous year, the firm posted ($0.61) EPS. The company’s revenue for the quarter was down 65.0% compared to the same quarter last year. On average, sell-side analysts expect that Seer, Inc. will post -1.08 earnings per share for the current year.
A number of institutional investors and hedge funds have recently bought and sold shares of SEER. SG Americas Securities LLC bought a new stake in Seer in the 4th quarter valued at $578,000. BlackRock Inc. acquired a new position in Seer in the 4th quarter valued at $3,072,000. Jennison Associates LLC acquired a new position in Seer in the 4th quarter valued at $9,296,000. Primecap Management Co. CA acquired a new position in Seer in the 4th quarter valued at $4,306,000. Finally, New York State Common Retirement Fund acquired a new position in Seer in the 4th quarter valued at $283,000. Institutional investors and hedge funds own 69.97% of the company’s stock.
Seer, Inc, a life sciences company, engages in developing and commercializing products for researchers to unlock biological information. The company develops Proteograph Product Suite, an integrated solution that comprises consumables, an automation instrumentation, and software that provides workflow to make proteomic profiling, and the analysis of the samples needed to characterize the nature of the proteome.
Further Reading: How to Use the MarketBeat Retirement Calculator
Receive News & Ratings for Seer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seer and related companies with MarketBeat.com's FREE daily email newsletter.